Stock reports › US › Healthcare

Merck & Co., Inc. (MRK) stock analysis

Merck pulls back from highs into Oct 29 earnings, with GAAP losses clouding a strong 1-year run

Merck closed at 141.82 on Oct 27, 2026, about 9.62% below its 52-week high of 156.92, after a 62.10% one-year gain. Trailing earnings are depressed (EPS of 1.25) after GAAP losses in the first two quarters of fiscal 2026, while forward P/E is 15.41. Q3 earnings are due Oct 29, 2026, with options pricing a 3.36% implied move.

  • Price: 141.82
  • Market Cap (USD): $350.58B
  • P/E: 110.49×
  • Fwd P/E: 15.41×
  • Div Yield: 2.40%
  • 1Y Return: 62.10%
  • Next Earnings: Oct 29, 2026
  • Mean Target: 156.76
  • Rating: Strong Buy

Bull case

  • Revenue is still growing, with year-over-year growth of 4.24% and 5.11% in the latest quarter, and free cash flow was $16.06B on a trailing basis (24.19% margin).
  • Analysts' mean target price is 156.76, 10.53% above the current price, and on Oct 28, 2026 the consensus showed 26 Buy, 11 Hold and 1 Sell ratings; Barclays raised its target to 180 from 150 on Oct 26.
  • The stock is 12.41% above its 200-day average of 126.17, with a relative strength rating of 92 and a year-to-date return of 34.73%.

Bear case

  • Reported profitability collapsed: Q1 and Q2 of fiscal 2026 had net losses of -4.24B and -1.33B, and trailing net margin is 4.78% versus a payout ratio of 272.00%.
  • Leverage is elevated, with total debt of 53.91B, net debt to EBITDA of 3.36x, and debt-to-equity in the 86th percentile of US Healthcare.
  • Short-term momentum has faded: price is 3.43% below the 50-day average, the 5-day return is -4.37%, and 13 insider sales (net -25.6M) were recorded in the last 90 days with no buys.

What to watch

  • Q3 earnings on Oct 29, 2026 (confirmed); consensus EPS is 2.09 and the options market implies a 3.36% move.
  • The 50-day average at 146.85 and 20-day average at 144.42 as overhead resistance; 20-day low of 138.80 as nearby support.
  • The 52-week and all-time high of 156.92 versus the 200-day average of 126.17 as outer bounds.
  • Next dividend: the last ex-date was Sep 15, 2026 (0.85 per share, quarterly); the next ex-date is not in the facts.

General

Merck is a large healthcare company selling prescription medicines, vaccines, biologic therapies, animal health and consumer care products. Revenue is growing modestly and the stock has rallied strongly, but reported earnings are depressed and results are due Oct 29, 2026.

Business and recent trend

The Pharmaceutical segment was 89.43% of fiscal 2025 revenue (58.14B) and Animal Health 9.77% (6.35B). The US contributed 56.16% of revenue. Trailing revenue is $66.40B, up 4.24% year over year, with the latest quarter at 16.61B.

Valuation in context

Forward P/E is 15.41 (based on the following fiscal year's consensus EPS of 9.20), in the 38th percentile of US Healthcare against a sector median of 17.62. Trailing P/E of 110.49 reflects depressed trailing EPS of 1.25. Dividend yield is 2.40%.

Market and analyst signals

On Oct 28, 2026, analysts rated the stock 26 Buy, 11 Hold, 1 Sell. The mean target is 156.76 from 13 analysts in the snapshot. News flow includes Phase III oncology results and the upcoming Q3 report.

Long-term investor

Merck combines high gross margins and strong cash flow with weak recent GAAP earnings and a heavier balance sheet. Growth durability and the rebound in earnings expected for next year are the key questions.

Growth and margins

Revenue grew 9.35% annually over five years but 3.08% over three. Fiscal 2025 revenue was 64.93B with net income of 18.25B, yet trailing operating margin is 16.65%, down 16.95% over the year. Gross margin is 75.38%, in the 76th percentile.

Returns and balance sheet

ROIC is 9.85% (sector median 10.40%) and ROE 6.98%. Debt is 53.91B against cash of 7.14B; interest coverage is 8.75x and the current ratio 1.32x. Piotroski F-Score is 4 and quality score is in the 10th percentile of the sector.

Capital returned and ownership

Dividends paid were 8.18B and buybacks 5.08B in fiscal 2025; shares outstanding fell 1.63% over a year. The dividend has grown for 15 years, with the quarterly payout at 0.85. Institutions own 82.27%; insiders sold 13 times in 90 days (net -25.6M).

Swing trader

The primary uptrend is intact above the 200-day average, but the stock has slipped below its 20- and 50-day averages with soft momentum. Earnings on Oct 29, 2026 fall inside the window.

Trend and momentum

Price of 141.82 sits below the 20-day (144.42) and 50-day (146.85) averages and above the 200-day (126.17). RSI is 44.66, MACD is -0.29 under its signal of 0.09, and ADX of 15.95 signals a weak trend. The 50-day average has been above the 200-day since the Oct 30, 2025 golden cross.

Levels and recent sessions

The 20-day range runs 138.80 to 154.02; the 52-week high is 156.92. On Oct 26 the stock fell to 140.61 on 13.1M shares, then gained 0.86% on Oct 27 on lighter volume (9.1M). ATR is 4.37 (3.08% of price).

Catalysts and positioning

Earnings fall on Oct 29, 2026. Short interest was 26.8M shares (1.09% of float) on Oct 15, 2026, down 5.12%. Recent analyst actions were mainly reiterations, with Barclays raising its target to 180 on Oct 26.

Options

Implied volatility is elevated relative to its own history and above realized volatility, with earnings inside the 30-day expiry. Liquidity is strong and the term structure is flat.

Volatility level

30-day implied volatility is 33.53%, with an IV rank of 74 and percentile of 83 against a 52-week range of 15.91% to 39.68%. It fell 4.2 points over five days. Realized 30-day volatility is 28.20%, a 1.19x IV/HV ratio, so premium is moderately rich.

Term structure and expected moves

IV60 is 32.51% and IV90 32.67%, a flat structure with a -0.9 point slope. The 25-delta skew is -0.9 points. The market implies a 4.64% move over 7 days and 9.61% over 30 days.

Earnings and premium yields

The implied earnings move is 3.36%, versus an eight-quarter average of 3.43% and a four-quarter average of 1.65%; the largest was 10.14%. Average IV crush is 6.90%. For the Nov 27, 2026 expiry, cash-secured put yield is 14.63% annualized and covered call yield 22.00%.

Liquidity and flow

Options volume was 34.1K, in line with the 20-day average, with open interest of 522.0K and a liquidity score of 93. Put/call volume is 0.73x and net call premium was $39.2M on the day.

Analysis written October 28, 2026 from Qanvo data as of October 27, 2026. AI-generated, for information only; not investment advice.